Welcome to our dedicated page for Lyell Immunopharma news (Ticker: LYEL), a resource for investors and traders seeking the latest updates and insights on Lyell Immunopharma stock.
Lyell Immunopharma, Inc. (NYSE: LYEL) is a clinical-stage biotechnology company developing novel T-cell therapies for solid tumors and hematologic malignancies through proprietary genetic/epigenetic reprogramming technologies. This page serves as the definitive source for verified company announcements, research breakthroughs, and regulatory developments.
Investors and researchers will find timely updates on Lyell's innovative pipeline including CAR T-cell candidates LYL797 and LYL119, tumor-infiltrating lymphocyte therapy LYL845, and dual-targeting IMPT-314 from the ImmPACT Bio acquisition. Our curated news collection covers essential developments across three key areas:
Clinical Trial Milestones: Phase 1/2 updates, patient enrollment progress, and safety/efficacy data disclosures
Research Innovations: Peer-reviewed study publications, ASCO/SITC presentations, and new patent filings
Strategic Developments: Manufacturing partnerships, leadership appointments, and regulatory pathway updates
Bookmark this page for direct access to Lyell's official press releases, SEC filings, and scientifically validated progress reports. Check regularly for updates on technologies addressing T-cell exhaustion and improving durable response rates in cancer immunotherapy.
Lyell Immunopharma (Nasdaq: LYEL) reported significant progress in Q2 2025, highlighted by positive clinical data for their lead program LYL314, a dual-targeting CD19/CD20 CAR T-cell therapy for large B-cell lymphoma. The Phase 1/2 trial showed impressive results with an 88% overall response rate and 72% complete response rate in 3L+ patients.
The company has initiated the PiNACLE pivotal trial for third-line or later treatment and plans to begin a second-line trial by early 2026. Additionally, Lyell secured a $100 million private placement, with an initial closing of $50 million. The company's pro-forma cash position of $347 million is expected to fund operations through mid-2027.
Q2 2025 financial results showed a net loss of $42.7 million, an improvement from $45.8 million in Q2 2024, with R&D expenses decreasing to $34.9 million from $40.3 million year-over-year.
Lyell Immunopharma (Nasdaq: LYEL), a clinical-stage CAR T-cell therapy company, has secured a private placement agreement worth up to $100 million with institutional and accredited investors. The deal includes an initial $50 million closing at $13.32 per share, expected on July 25, 2025, with potential for an additional $50 million tied to clinical milestones.
The financing includes flexible terms with milestone-based pricing ranging from $10.41 to $25.61 per share and investor call options at $30.73 per share. The proceeds will fund two pivotal-stage trials of LYL314, including the PiNACLE trial for large B-cell lymphoma, and extend the company's cash runway into mid-2027.
Lyell Immunopharma (Nasdaq: LYEL) announced its participation in the H.C. Wainwright "HCW@Home" Series on June 25, 2025. The virtual fireside chat will feature CEO Lynn Seely and CFO Charlie Newton discussing their lead product LYL314, a dual-targeting CD19/CD20 CAR T-cell therapy for large B-cell lymphoma (LBCL).
The presentation will highlight recent positive clinical data presented at ICML and focus on next-generation CAR T-cell therapies. LYL314, which has received both RMAT and Fast Track designations from the FDA, aims to improve complete response rates and response duration compared to existing CD19-targeted therapies.
Lyell Immunopharma (LYEL) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its LYL314 therapy, targeting relapsed/refractory large B-cell lymphoma. The designation was based on promising data from an ongoing Phase 1/2 trial.
Key clinical results include:
- 94% overall response rate (16/17 patients)
- 71% complete response rate (12/17 patients)
- 71% of patients maintaining response at last follow-up
- Median follow-up of 6.3 months
- No Grade 3+ cytokine release syndrome reported
LYL314 is a dual-targeting CD19/CD20 CAR T-cell therapy designed to improve complete response rates compared to existing treatments. The company plans to initiate two pivotal programs: one in mid-2025 for 3rd+ line treatment and another in early 2026 for 2nd line treatment. Additional clinical updates are expected throughout 2025.
Lyell Immunopharma (LYEL) reported its Q4 and full-year 2024 results, highlighting significant developments in its CAR T-cell therapy pipeline. The company's lead program, IMPT-314, showed promising Phase 1 data with a 94% overall response rate and 71% complete response rate in large B-cell lymphoma patients.
Key financial metrics include a net loss of $191.9M for Q4 and $343.0M for full-year 2024. Cash position stands at $383.5 million, expected to fund operations into 2027. The company plans to initiate pivotal trials for IMPT-314 in mid-2025 for 3rd line treatment and early 2026 for 2nd line treatment.
Research and development expenses were $48.7M in Q4 and $171.6M for the full year. The company acquired ImmPACT Bio, incurring $87.2M in IPR&D expenses, and recorded a $51.3M impairment charge on long-lived assets due to stock price decline.